As Passed by the House

132nd General Assembly

Regular Session 2017-2018

Sub. H. B. No. 167

Representative Edwards

Cosponsors: Representatives Householder, Anielski, Antani, Antonio, Arndt, Blessing, Brenner, Brown, Butler, Carfagna, Clyde, Craig, Cupp, Dever, Gavarone, Ginter, Gonzales, Green, Hagan, Hambley, Henne, Hoops, Hughes, Ingram, Johnson, Keller, Kick, Landis, Lanese, Lang, Leland, Manning, McClain, Merrin, Miller, O'Brien, Patterson, Patton, Pelanda, Perales, Reineke, Riedel, Roegner, Rogers, Romanchuk, Ryan, Scherer, Schuring, Seitz, Sheehy, Smith, T., Stein, Thompson, West, Wiggam, Wilkin, Young, Speaker Smith

A BILL

То	amend sections 4723.52, 4730.56, 4731.83, and	1
	5119.363, to amend, for the purpose of adopting	2
	a new section number as indicated in	3
	parentheses, section 3715.08 (3719.064), and to	4
	enact sections 3719.063 and 4729.283 of the	5
	Revised Code regarding naltrexone and	6
	medication-assisted treatment.	7

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:

Section 1. That sections 4723.52, 4730.56, 4731.83, and	8
5119.363 be amended, section 3715.08 (3719.064) be amended for	9
the purpose of adopting a new section number as indicated in	10
parentheses, and sections 3719.063 and 4729.283 of the Revised	11
Code be enacted to read as follows:	12
Sec. 3719.063. In the absence of gross negligence or	13
growth of the discourse of growth hoging ones of	
intentional misconduct, a person who administers the drug	1 4

<u>naltrexone</u> by injection, the person's employer, and the facility	15
at which the drug is administered are not liable in any civil	16
action or subject to criminal prosecution or professional	17
discipline for any injury or damage caused by the injection or	18
drug if all of the following conditions are met:	19
(A) The individual to whom the drug is administered is	20
unable to have it administered as follows:	21
(1) By a person who routinely administers the drug to the	22
<pre>individual;</pre>	23
(2) At the facility at which the drug is routinely	24
administered to the individual;	25
(3) Under the direction of the drug's prescriber.	26
(B) The person who administers the drug under this section	27
is legally authorized to administer it by injection but is not	28
the prescriber of the drug or one who routinely administers it	29
to the individual.	30
(C) The drug is provided to the person who administers it	31
under this section in either of the following ways:	32
(1) By the individual to whom it is administered;	33
(2) By the pharmacy that has a record of a prescription	34
for the drug in the name of the individual to whom it is	35
administered.	36
(D) The person who administers the drug under this section	37
is authorized to do so by that person's employer or the facility	38
at which the drug is administered.	39
Sec. 3715.08 3719.064. (A) As used in this section:	40
(1) "Medication-assisted treatment" has the same meaning	41

as in section 340.01 of the Revised Code.	42
(2) "Prescriber" means any of the following:	43
(a) An advanced practice registered nurse who holds a	44
current, valid license issued under Chapter 4723. of the Revised	45
Code and is designated as a clinical nurse specialist, certified	46
nurse-midwife, or certified nurse practitioner;	47
(b) A physician authorized under Chapter 4731. of the	48
Revised Code to practice medicine and surgery or osteopathic	
medicine and surgery;	50
(c) A physician assistant who is licensed under Chapter	51
4730. of the Revised Code, holds a valid prescriber number	52
issued by the state medical board, and has been granted	53
physician-delegated prescriptive authority.	54
(3) "Qualifying practitioner" has the same meaning as in	55
section 303(g)(2)(G)(iii) of the "Controlled Substances Act of	56
1970," 21 U.S.C. 823(g)(2)(G)(iii), as amended.	57
(B) Before initiating medication-assisted treatment, a	58
prescriber shall give the patient or the patient's	59
representative information about all drugs approved by the	60
United States food and drug administration for use in	61
medication-assisted treatment. The information must be provided	62
both orally and in writing. The prescriber or the prescriber's	63
delegate shall note in the patient's medical record when this	64
information was provided and make the record available to	65
employees of the board of nursing or state medical board on	66
their request.	67
If the prescriber is not a qualifying practitioner and the	68
patient's choice is treatment with a controlled substance	69
containing buprenorphine and the prescriber determines that such	70

99

treatment is clinically appropriate and meets generally accepted	71
standards of medicine, the prescriber shall refer the patient to	72
a qualifying practitioner. If the patient's choice is methadone	73
treatment and the prescriber determines that such treatment is	74
clinically appropriate and meets generally accepted standards of	75
medicine, the prescriber shall refer the patient to a community	76
addiction services provider licensed under section 5119.391 of	77
the Revised Code. In either case, the prescriber or the	78
prescriber's delegate shall make a notation in the patient's	79
medical record naming the practitioner or provider to whom the	80
patient was referred and specifying when the referral was made.	81
Sec. 4723.52. (A) As used in this section:	82
(1) "Community addiction services provider" has the same	83
meaning as in section 5119.01 of the Revised Code.	84
(2) "Medication-assisted treatment" has the same meaning	85
as in section 340.01 of the Revised Code.	86
(B) An advanced practice registered nurse shall comply	87
with section $\frac{3715.08}{3719.064}$ of the Revised Code and rules	88
adopted under section 4723.51 of the Revised Code when treating	89
a patient for addiction with medication-assisted treatment or	90
proposing to initiate such treatment.	91
(C) An advanced practice registered nurse who fails to	92
comply with this section shall treat not more than thirty	93
patients at any one time with medication-assisted treatment even	94
if the facility or location at which the treatment is provided	95
is either of the following:	96
(1) Exempted by divisions (B)(2)(a) to (d) of section	97
4729.553 of the Revised Code from being required to possess a	98

category III terminal distributor of dangerous drugs license

with an office-based opioid treatment classification;	100
(2) A community addiction services provider that provides	101
alcohol and drug addiction services that are certified by the	102
department of mental health and addiction services under section	103
5119.36 of the Revised Code.	104
Sec. 4729.283. (A) A pharmacist may dispense naltrexone	105
without a written or oral prescription from a licensed health	106
professional authorized to prescribe drugs if all of the	107
<pre>following conditions are met:</pre>	108
(1) The pharmacist is able to verify a record of a	109
prescription for the injectable long-acting or extended-release	110
form of naltrexone in the name of the patient who is requesting	111
the drug, but the prescription does not provide for a refill or	112
the time permitted by rules adopted by the state board of	113
pharmacy for providing refills has elapsed.	114
(2) The pharmacist is unable to obtain authorization to	115
refill the prescription from the prescriber who issued it or	116
another prescriber responsible for the patient's care.	117
(3) In the exercise of the pharmacist's professional	118
<pre>judgment:</pre>	119
(a) The drug is necessary to continue the patient's	120
therapy for substance use disorder.	121
(b) Failure to dispense the drug to the patient could	122
result in harm to the health of the patient.	123
(B) Before dispensing naltrexone under this section, the	124
pharmacist shall offer the patient the choice of receiving	125
either the oral form or injectable long-acting or extended-	126
release form, but only if both forms of the drug are available	127

for dispensing at the time of the patient's request or within	128
one day after the request.	129
(C)(1) With respect to naltrexone dispensed in an oral	130
form under this section, the pharmacist shall not dispense an	131
amount that exceeds a five-day supply.	132
(2) With respect to naltrexone dispensed in an injectable	133
long-acting or extended-release form under this section, both of	134
the following apply:	135
(a) The pharmacist shall exercise professional judgment in	136
determining the amount of the drug dispensed.	137
(b) The pharmacist may administer the drug by injection to	138
the patient but only in accordance with section 4729.45 of the	139
Revised Code.	140
(D) A pharmacist who dispenses naltrexone under this	141
section shall do all of the following:	142
(1) For one year after the date of dispensing, maintain a	143
record in accordance with this chapter of the drug dispensed,	144
including the amount and form dispensed, the original	145
prescription number, the name and address of the patient and, if	146
the individual receiving the drug is not the patient, the name	147
and address of that individual;	148
(2) Notify the prescriber who issued the prescription	149
described in division (A)(1) of this section or another	150
prescriber responsible for the patient's care not later than	151
five days after the drug is dispensed;	152
(3) If applicable, obtain authorization for additional	153
dispensing from one of the prescribers described in division (D)	154
(2) of this section	155

(E) A pharmacist shall exercise professional judgment in	156
determining the number of times naltrexone may be dispensed	157
under this section to the same patient.	158
(F) This section does not limit the authority of a	159
pharmacist to dispense a dangerous drug under section 4729.281	160
of the Revised Code.	161
Sec. 4730.56. (A) As used in this section:	162
(1) "Community addiction services provider" has the same	163
meaning as in section 5119.01 of the Revised Code.	164
(2) "Medication-assisted treatment" has the same meaning	165
as in section 340.01 of the Revised Code.	166
(B) A physician assistant shall comply with section	167
3715.08 3719.064 of the Revised Code and rules adopted under	168
section 4730.55 of the Revised Code when treating a patient with	169
medication-assisted treatment or proposing to initiate such	170
treatment.	171
(C) A physician assistant who fails to comply with this	172
section shall treat not more than thirty patients at any one	173
time with medication-assisted treatment even if the facility or	174
location at which the treatment is provided is either of the	175
following:	176
(1) Exempted by divisions (B)(2)(a) to (d) of section	177
4729.553 of the Revised Code from being required to possess a	178
category III terminal distributor of dangerous drugs license	179
with an office-based opioid treatment classification;	180
(2) A community addiction services provider that provides	181
alcohol and drug addiction services that are certified by the	182
department of mental health and addiction services under section	183

5119.36 of the Revised Code.	184
Sec. 4731.83. (A) As used in this section:	185
(1) "Medication-assisted treatment" has the same meaning	186
as in section 340.01 of the Revised Code.	187
(2) "Physician" means an individual authorized by this	188
chapter to practice medicine and surgery or osteopathic medicine	189
and surgery.	190
(B) A physician shall comply with section 3715.08 3719.064	191
of the Revised Code and rules adopted under section 4731.056 of	192
the Revised Code when treating a patient with medication-	193
assisted treatment or proposing to initiate such treatment.	194
(C) A physician who fails to comply with this section	195
shall treat not more than thirty patients at any one time with	196
medication-assisted treatment even if the facility or location	197
at which the treatment is provided is either of the following:	198
(1) Exempted by divisions (B)(2)(a) to (d) of section	199
4729.553 of the Revised Code from being required to possess a	200
category III terminal distributor of dangerous drugs license	201
with an office-based opioid treatment classification;	202
(2) A community addiction services provider that provides	203
alcohol and drug addiction services that are certified by the	204
department of mental health and addiction services under section	205
5119.36 of the Revised Code.	206
Sec. 5119.363. The director of mental health and addiction	207
services shall adopt rules governing the duties of boards of	208
alcohol, drug addiction, and mental health services under	209
section 340.20 of the Revised Code and the duties of community	210
addiction services providers under section 5119.362 of the	211

Sub. H. B. No. 167 As Passed by the House	
Revised Code. The rules shall be adopted in accordance with	212
Chapter 119. of the Revised Code.	213
The director shall adopt rules under this section that	214
authorize the department of mental health and addiction services	215
to determine an advanced practice registered nurse's, physician	216
assistant's, or physician's compliance with section 3715.08	217
3719.064 of the Revised Code if such practitioner works for a	218
community addiction services provider.	219
Section 2. That existing section 3715.08, 4723.52,	220
4730.56, 4731.83, and 5119.363 of the Revised Code are hereby	221
repealed.	222
Section 3. This act shall be known as "Daniel's Law."	223